TY - JOUR
T1 - Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
AU - Chauvin, Camille
AU - Levillayer, Laurine
AU - Roumier, Mathilde
AU - Nielly, Hubert
AU - Roth, Claude
AU - Karnam, Anupama
AU - Bonam, Srinivasa Reddy
AU - Bourgarit, Anne
AU - Dubost, Clément
AU - Bousquet, Aurore
AU - Le Burel, Sébastien
AU - Mestiri, Raphaële
AU - Sene, Damien
AU - Galland, Joris
AU - Vasse, Marc
AU - Groh, Matthieu
AU - Le Marchand, Mathilde
AU - Vassord-Dang, Camille
AU - Gautier, Jean François
AU - Pham-Thi, Nhan
AU - Verny, Christiane
AU - Pitard, Bruno
AU - Planchais, Cyril
AU - Mouquet, Hugo
AU - Paul, Richard
AU - Simon-Loriere, Etienne
AU - Bayry, Jagadeesh
AU - Gilardin, Laurent
AU - Sakuntabhai, Anavaj
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/3/17
Y1 - 2023/3/17
N2 - Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.
AB - Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.
KW - Health sciences
KW - Immunology
KW - Virology
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85147905642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147905642&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2023.106124
DO - 10.1016/j.isci.2023.106124
M3 - Article
C2 - 36776936
AN - SCOPUS:85147905642
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 3
M1 - 106124
ER -